Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI‐mediated basophil activation by a tumour‐specific IgE antibody to evaluate the risk of type I hypersensitivity
Sarah Maria Rudman(Guy's and St Thomas' NHS Foundation Trust), Sophia N. Karagiannis(King's College London), Alexander Koers, Helen Cambrook(King's College London), Andrew J. Beavil(St Thomas' Hospital), Christopher F. Nicodemus(Advanced Immune Therapeutics (United States)), James Spicer(King's College London), Frank O. Nestlé(Guy's and St Thomas' NHS Foundation Trust), Silvana Canevari(Institute of Biomedical Technologies), Tihomir Dodev(St Thomas' Hospital), Debra H. Josephs(Guy's and St Thomas' NHS Foundation Trust), Philip J. Blower(King's College London), Christopher J. Corrigan(King's College London), Panagiotis Karagiannis(St Thomas' Hospital), James Hunt(AstraZeneca (United Kingdom)), Hannah J. Gould(King's College London), Mariangela Figini(Fondazione IRCCS Istituto Nazionale dei Tumori), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Amy E. Gilbert(St Thomas' Hospital), S.B. Kaye(Western Infirmary), Leonie S. Taams(King's College London)
Cited by 41
Related Papers
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
|Nature Genetics|2010|1.1k
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
|Nature Genetics|2012|1k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-α
|The Journal of Experimental Medicine|2004|513
Targeting folate receptor alpha for cancer treatment
|Oncotarget|2016|447